Navigation Links
Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Date:9/17/2009

the end of the trial to assess heart valve function over time. In contrast to the BLOOM trial, there were no echocardiographic exclusion criteria for entry into BLOSSOM and there was no oversight or interim data review monitoring by an independent safety monitoring board.

Phase 3 Program Overview

The lorcaserin Phase 3 program consists of three trials: BLOOM, BLOSSOM and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus). Enrollment in the lorcaserin Phase 3 program is complete with approximately 7,800 patients. Positive results from BLOOM were presented at the 69th Scientific Sessions of the American Diabetes Association in June 2009. BLOOM and BLOSSOM comprise the Phase 3 pivotal registration program and will be the basis for the lorcaserin NDA submission. BLOOM-DM, which is planned as a supplement to the NDA, is evaluating 10 mg of lorcaserin dosed once or twice daily versus placebo over a one-year treatment period in obese and overweight patients with type 2 diabetes at about 60 sites in the US.

A standardized program of moderate diet and exercise guidance is included in the Phase 3 program. The program's hierarchically ordered co-primary efficacy endpoints are: the proportion of patients achieving 5% or greater weight loss after 12 months, the difference in mean weight loss compared to placebo after 12 months, and the proportion of patients achieving 10% or greater weight loss after 12 months. Arena is also studying several key secondary endpoints, including changes in serum lipids, markers of inflammation and insulin resistance, and in the BLOOM-DM trial, other indicators of glycemic control.

About the FDA Draft Guidance

The FDA draft guidance document "Developing Products for Weight Management" dated February 2007 provides recommendations regarding the development of drugs for t
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... WASHINGTON and NEW YORK ... 2014 As the leading distributor of market ... a new research report by IQ4I Research and Consultancy ... To learn more about IQ4I Research visit: ... Active Pharmaceutical Ingredients Global Market – Forecast ...
(Date:11/26/2014)... 25, 2014 Reinforcing its commitment to enabling ... PHG AEX: PHIA) today announced 510(k) ... for its IQon Spectral CT , presenting an ... technology adds a new dimension to Computed Tomography (CT) ... characterize structures based on their material content within a ...
(Date:11/26/2014)... Pa. , Nov. 25, 2014  Unilife Corporation ... of injectable drug delivery systems, today announced that its ... to present at the Piper Jaffray 26th Annual Healthcare ... a.m. EST on Tuesday, December 2, 2014. ... Internet as a "live" listen only Webcast. To listen, ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2
(Date:11/27/2014)... Vancouver, BC (PRWEB) November 27, 2014 ... http://www.idataresearch.com ), those companies looking to break into the ... in other medical specialties, other than the MIS field ... almost one-third of the U.S. surgical robotics market by ... nearing saturation,” explains Dr. Kamran Zamanian, CEO and President ...
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer from an embarrassing fact of life, and she ... musty a few minutes later, I decided that there ... longer periods," she said. , Easy to use and ... maintains freshness in a woman’s private areas throughout the ...
(Date:11/27/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola vaccine appears to be safe and produces an ... virus, according to early clinical trial results reported by the ... phase I clinical trial for the vaccine paves the way ... Liberia and Sierra Leone as early as January, said Dr. ...
(Date:11/27/2014)... Now that Thanksgiving is finally here and ... Emassagechair.com has announced its eagerly awaited, once yearly ... Negotiating on behalf of their customers, and drawing on ... has generated significant buzz in the industry with the ... , Shoppers are excited for significant savings available on ...
(Date:11/27/2014)... 2014 “LAB.C” was featured on NewsWatch as ... and coolest technology products available to consumers. Mallory Sofastaii, a ... review and shared with viewers the company offers a ... devices. , Consumers love portability and functionality. A unique ... for the iPhone5 and 5S has a portable USB charger ...
Breaking Medicine News(10 mins):Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2
... to restart production of missing protein , TUESDAY, Aug. ... muscle appears to jump-start the production of a crucial ... British researchers report. , The treatment so far is ... the debilitating and ultimately fatal disease, but scientists are ...
... , , , ... over $800,000 on prescription drugs through Iowa Drug Card since the launch ... free discount drug cards to Iowa residents, was launched in June, 2008. ... program. , , Former Hawkeye,s Head Football Coach ...
... TSX: COM, , , VANCOUVER, Aug. 25 ... ("Cardiome" or the "Company") announced today that its Board of ... to purchase for cancellation up to 6,470,588 of its common ... million. The offer will be conducted as a modified "Dutch ...
... , IRVINE, Calif., Aug. 25 CorVel Corporation ... Board of Directors has approved a 1,000,000 share expansion to its ... for repurchase over the life of the program to 14,150,000 shares. ... program in the fall of 1996. From the program,s inception through ...
... , CHARLES TOWN, W.Va., Aug. 25 ReBuilder ... treatments for the pain resulting from Peripheral Neuropathy and Peripheral ... and is now reporting profits for the first Quarter of ... ) , , "Our efforts to ...
... , , CENTER CITY, ... helps people reclaim their lives from addiction, has appointed William ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20061128/CGTU038LOGO ) , (Photo: ... to announce the appointment of William C. Moyers as Vice ...
Cached Medicine News:Health News:Experimental Treatment Could Fight Muscular Dystrophy 2Health News:Iowa Drug Card a Huge Success With Iowans 2Health News:Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares 2Health News:Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares 3Health News:Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares 4Health News:Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares 5Health News:Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares 6Health News:CorVel Announces Expansion to Share Buyback Program 2Health News:CorVel Announces Expansion to Share Buyback Program 3Health News:ReBuilder Medical Technologies, Inc. Announces First Quarter 2009 is Profitable 2Health News:William C. Moyers Appointed Vice President of Foundation Relations for Hazelden 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: